加拿大成人三个流感季节中三价流感疫苗预防流感相关住院及严重结局的效果:加拿大免疫研究网络严重结局监测网络的汇总分析
该研究基于加拿大免疫研究网络严重结局监测网络在2011/12至2013/14三个流感季的主动监测,采用检测阴性设计,纳入3394例病例和4560例对照,评估三价流感疫苗预防实验室确诊流感相关住院及其他严重结局的效果。总体调整疫苗效果为41.7%(95%CI:34.4-48.3%),≥65岁成人为39.3%(95%CI:29.4-47.8%),<65岁成人为48.0%(95%CI:37.5-56.7%)。作者认为三价流感疫苗在三个季节中对预防住院和其他严重结局显示出有统计学意义且临床重要的疫苗效果,但效果逐年波动。
要点
- 总体调整疫苗效果为41.7%(95%CI:34.4-48.3%),≥65岁为39.3%(95%CI:29.4-47.8%),<65岁为48.0%(95%CI:37.5-56.7%)。
- 所有年龄组预防流感相关ICU入住/机械通气的疫苗效果为54.1%(95%CI:39.8-65.0%)。
- ≥65岁成人预防流感相关死亡的疫苗效果为74.5%(95%CI:44.0-88.4%)。
核心结论
- 三价流感疫苗在三个流感季节中对预防住院和其他严重结局显示出有统计学意义且临床重要的疫苗效果,但效果逐年波动。
- 公共卫生信息应强调流感疫苗的总体获益,同时承认逐年变异性。
研究设计与样本
- 加拿大免疫研究网络严重结局监测网络在2011/2012、2012/2013和2013/2014三个流感季于加拿大各医院对≥16岁成人开展主动监测。
- 采用检测阴性设计:病例为聚合酶链反应(PCR)流感阳性,对照为PCR流感阴性,并按日期、入院地点和年龄(≥65岁或<65岁)与病例匹配。
- 所有病例和对照从病历中获取人口学和临床特征(包括流感免疫状态)。
- 疫苗效果估计为1-比值比(OR)(接种 vs 未接种患者)×100%。
- 共纳入3394例病例和4560例对照;2078例(61.2%)病例和2939例(64.5%)对照为≥65岁。
主要发现
- 总体匹配调整疫苗效果为41.7%(95%CI:34.4-48.3%)。
- ≥65岁成人疫苗效果为39.3%(95%CI:29.4-47.8%),<65岁成人为48.0%(95%CI:37.5-56.7%)。
- 所有年龄组预防流感相关ICU入住/机械通气的疫苗效果为54.1%(95%CI:39.8-65.0%)。
- ≥65岁成人预防流感相关死亡的疫苗效果为74.5%(95%CI:44.0-88.4%)。
关键数值与推荐
- 主要结局为三价流感疫苗预防实验室确诊流感相关住院的疫苗效果。
- 次要结局包括三价流感疫苗预防流感相关ICU入住/机械通气以及流感相关死亡的疫苗效果。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Ongoing assessment of influenza vaccine effectiveness (VE) is critical to inform public health policy. This study aimed to determine the VE of trivalent influenza vaccine (TIV) for preventing influenza-related hospitalizations and other serious outcomes over three consecutive influenza seasons. METHODS: The Serious Outcomes Surveillance (SOS) Network of the Canadian Immunization Research Network (CIRN) conducted active surveillance for influenza in adults ≥16 years (y) of age during the 2011/2012, 2012/2013 and 2013/2014 seasons in hospitals across Canada. A test-negative design was employed: cases were polymerase chain reaction (PCR)-positive for influenza; controls were PCR-negative for influenza and were matched to cases by date, admission site, and age (≥65 y or <65 y). All cases and controls had demographic and clinical characteristics (including influenza immunization status) obtained from the medical record. VE was estimated as 1-OR (odds ratio) in vaccinated vs. unvaccinated patients × 100%. The primary outcome was VE of TIV for preventing laboratory-confirmed influenza-related hospitalization; secondary outcomes included VE of TIV for preventing influenza-related intensive care unit (ICU) admission/mechanical ventilation, and influenza-related death. RESULTS: Overall, 3394 cases and 4560 controls were enrolled; 2078 (61.2%) cases and 2939 (64.5%) controls were ≥65 y. Overall matched, adjusted VE was 41.7% (95% Confidence Interval (CI): 34.4-48.3%); corresponding VE in adults ≥65 y was 39.3% (95% CI: 29.4-47.8%) and 48.0% (95% CI: 37.5-56.7%) in adults <65 y, respectively. VE for preventing influenza-related ICU admission/mechanical ventilation in all ages was 54.1% (95% CI: 39.8-65.0%); in adults ≥65 y, VE for preventing influenza-related death was 74.5% (95% CI: 44.0-88.4%). CONCLUSIONS: While effectiveness of TIV to prevent serious outcomes varies year to year, we demonstrate a statistically significant and clinically important TIV VE for preventing hospitalization and other serious outcomes over three seasons. Public health messaging should highlight the overall benefit of influenza vaccines over time while acknowledging year to year variability. ClinicalTrials.gov Identifier: NCT01517191.
引用
- Nichols MK, Andrew MK, Hatchette TF, et al. Influenza vaccine effectiveness to prevent influenza-related hospitalizations and serious outcomes in Canadian adults over the 2011/12 through 2013/14 influenza seasons: A pooled analysis from the Canadian Immunization Research Network (CIRN) Serious Outcomes Surveillance (SOS Network). Vaccine. 2018. PMID: 29548608. doi:10.1016/j.vaccine.2018.02.093
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。